MedTrace Logo

Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.

NCT00449553 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 326

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily (QD), treatment.

Conditions

Interventions

DRUG

Pioglitazone and sulphonylurea

Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.

DRUG

Pioglitazone and sulphonylurea

Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.

DRUG

Pioglitazone and metformin

Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.

DRUG

Pioglitazone and metformin

Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.

Sponsors & Collaborators

Principal Investigators

  • VP Clinical Science Strategy · Takeda Global Research and Developmnet Center Inc

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2003-09-30
Completion
2003-09-30

Countries

  • Denmark
  • Iceland
  • Norway
  • Sweden

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449553 on ClinicalTrials.gov